从胃心痛论治冠心病PCI术后胃黏膜损伤的诊疗经验  

Experience in Treatment of Gastric Mucosa Injury Induced by Antiplatelet Drug in Patients with Coronary Heart Disease

作　　者：秦彰 龙云[2] QIN Zhang;LONG Yun(Hunan University of Traditional Chinese Medicine,Changsha 410208,China;Department of Cardiovascular Medicine,the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine,Changsha 410007,China)

机构地区：[1]湖南中医药大学,湖南长沙410208 [2]湖南中医药大学第一附属医院心血管内科,湖南长沙410007

出　　处：《中国民族民间医药》2024年第13期68-71,共4页Chinese Journal of Ethnomedicine and Ethnopharmacy

基　　金：长沙市自然科学基金(kq2202459);湖南省卫生健康委基金(202203014389)。

摘　　要：冠心病患者在行PCI术后需长期服用抗血小板药物治疗,但长期服用抗血小板药物易致胃黏膜损伤,而单纯使用抑酸、护胃药物来治疗此类疾病,副作用多而收效不明显,且最新研究表明单纯使用PPI预防再次消化道出血时可能会增加心血管病患者心血管事件的发生率。因此,龙云主任从中医整体观念出发,从胃心痛角度来辨证论治本病,收效显著,可为临床治疗抗血小板药物致冠心病胃黏膜损伤患者提供新思路。Patients with coronary heart disease need long-term Antiplatelet drug therapy after Percutaneous coronary intervention,but long-term use of Antiplatelet drug may cause gastric mucosal damage,and the use of acid-inhibiting and stomach-protecting drugs alone to treat such diseases,side effects are many and the effect is not obvious,and recent studies have shown that Proton-pump inhibitor alone may increase the risk of cardiovascular events in patients with cardiovascular gastrointestinal bleeding.Therefore,director Long Yun from the overall concept of traditional Chinese medicine,syndrome differentiation and treatment from the point of view of stomach and heart pain to treat this disease,the results are significant.This article provides a new idea for the treatment of gastric mucosa injury caused by Antiplatelet drug in patients with coronary heart disease.

关 键 词：抗血小板药物 胃黏膜损伤 临床应用 心胃同治 

分 类 号：R249.2[医药卫生—中医临床基础] R249.7[医药卫生—中医学]